Congratulations to our client, Sol-Gel Technologies Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on developing innovative topical drug treatments for skin diseases, on its underwritten public offering of ordinary shares for gross proceeds of approximately $33 million.
Our team advising Sol-Gel in this transaction included: Perry Wildes and Ella Merhav of our International and Hi-Tech Department and Shay Fahima of our Tax Department.
